Among different subtypes of breast cancers, 18F-FDG PET/CT is generally more sensitive in TNBC than in HR+ and HER2+ breast cancers, as some HR+ and HER2+ breast tumors cannot be clearly visualized. This evidence concerns the gene ERBB2 and breast neoplasm.